Novo Nordisk A/S Common Stock (NY:NVO)

Viking aims to enter the billion-dollar weight loss drug market.

Topics Fraud Lawsuit

Down 34%, Should You Buy the Dip on Viking Therapeutics? ↗

September 05, 2025

Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO

September 04, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO

September 04, 2025

Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report ↗

Topics Fraud Lawsuit

September 03, 2025

Via Stocktwits

Where Will Eli Lilly Be in 3 Years? ↗

September 04, 2025

The weight-loss drug opportunity could approach $100 billion by the end of the decade.

There are new ways to tackle weight loss, but the stocks leading the way are lagging.

Topics Intellectual Property

The Problem With Weight Loss Stocks ↗

September 03, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Topics Economy

September 03, 2025

From Faruqi & Faruqi LLP

Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns.

After Copycat Boom, China's Drugmakers Target Global Generics ↗

September 03, 2025

Via Benzinga

Topics Supply Chain

Should You Buy Novo Nordisk Stock Now or Wait? ↗

September 03, 2025

NVO stock is down 60% over the past 12 months.

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 03, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 03, 2025

Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Topics Fraud Lawsuit

September 03, 2025

From Bragar Eagel & Squire

A 57% risk reduction for heart attacks and strokes sounds like an amazing result.

Is Novo Nordisk Stock a Buy Now? ↗

September 03, 2025

Marjorie Taylor Greene Hits Homerun Again, Buys Alphabet Stock 5 Days Before Favorable Antitrust Ruling: Here Are Some Other New Trades ↗

September 03, 2025

Rep. Marjorie Taylor Greene buys Google stock just days before a key antitrust ruling. See her latest trades and portfolio performance.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

September 02, 2025

From Pomerantz LLP

NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

September 02, 2025

From Bernstein Liebhard LLP

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 02, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 02, 2025

Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death ↗

Topics Fraud Lawsuit

September 02, 2025

Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

August 30, 2025

From Bragar Eagel & Squire

NOVO-NORDISK (NVO) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.

NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock ↗

August 30, 2025

Via Chartmill

Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook ↗

August 29, 2025

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

August 29, 2025

From Pomerantz LLP

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗

August 29, 2025

Investment bank analysts up and down Wall Street are pounding the table on these stocks.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

August 28, 2025

From Faruqi & Faruqi LLP

Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy.

Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda ↗

August 28, 2025

Via Benzinga

Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study ↗

August 28, 2025

Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.

Via Benzinga

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

August 28, 2025

From The Rosen Law Firm PA